Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Molecular engineering of therapeutic cytokines


Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here, we summarize past, recent and emerging strategies in this area.

Type Journal
Authors Vazquez-Lombardi, R.; Roome, B.; Christ, D.
Responsible Garvan Author (missing name)
Publisher Name Antibodies
Published Date 2013-08-01
Published Volume 2
Published Pages 426-451
Status Published in-print
DOI 10.3390/antib2030426
URL link to publisher's version
OpenAccess link to author's accepted manuscript version